

Ishwarlal Jialal,, Frepath, Dabcc, Dabel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1970708/publications.pdf>

Version: 2024-02-01

119
papers

3,559
citations

185998

28
h-index

138251

58
g-index

124
all docs

124
docs citations

124
times ranked

5205
citing authors

#	ARTICLE	IF	CITATIONS
1	C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?. Hypertension, 2004, 44, 6-11.	1.3	501
2	Toll-like Receptor Status in Obesity and Metabolic Syndrome: A Translational Perspective. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 39-48.	1.8	221
3	Human C-reactive protein and the metabolic syndrome. Current Opinion in Lipidology, 2009, 20, 182-189.	1.2	205
4	Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes. Clinica Chimica Acta, 2019, 496, 35-44.	0.5	182
5	Adipose Tissue Dysregulation in Patients with Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1782-E1788.	1.8	160
6	Evidence of Increased Inflammation and Microcirculatory Abnormalities in Patients With Type 1 Diabetes and Their Role in Microvascular Complications. Diabetes, 2007, 56, 2790-2796.	0.3	158
7	Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome. Diabetes Care, 2012, 35, 900-904.	4.3	146
8	Adipose Tissue Dysfunction in Nascent Metabolic Syndrome. Journal of Obesity, 2013, 2013, 1-8.	1.1	129
9	Increased Chemerin and Decreased Omentin-1 in Both Adipose Tissue and Plasma in Nascent Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E514-E517.	1.8	127
10	The Role of Oxidized Low Density Lipoprotein in Atherogenesis. Journal of Nutrition, 1996, 126, 1053S-1057S.	1.3	106
11	Divergence between LDL Oxidative Susceptibility and Urinary F2-Isoprostanes as Measures of Oxidative Stress in Type 2 Diabetes. Clinical Chemistry, 2001, 47, 1974-1979.	1.5	103
12	Hyperglycemia Induces Toll-Like Receptor-2 and -4 Expression and Activity in Human Microvascular Retinal Endothelial Cells: Implications for Diabetic Retinopathy. Journal of Diabetes Research, 2014, 2014, 1-15.	1.0	93
13	Increased Cellular and Circulating Biomarkers of Oxidative Stress in Nascent Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1844-E1850.	1.8	89
14	The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications. Current Diabetes Reports, 2012, 12, 172-179.	1.7	68
15	Global toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy. Journal of Diabetes and Its Complications, 2014, 28, 755-761.	1.2	68
16	Exploratory metabolomics of metabolic syndrome: A status report. World Journal of Diabetes, 2019, 10, 23-36.	1.3	64
17	Toll-like receptors 2 and 4 mediate hyperglycemia induced macrovascular aortic endothelial cell inflammation and perturbation of the endothelial glycocalyx. Journal of Diabetes and Its Complications, 2016, 30, 563-572.	1.2	63
18	Management of diabetic dyslipidemia: An update. World Journal of Diabetes, 2019, 10, 280-290.	1.3	58

#	ARTICLE	IF	CITATIONS
19	Increased adipose tissue secretion of Fetuin-A, lipopolysaccharide-binding protein and high-mobility group box protein 1 in metabolic syndrome. <i>Atherosclerosis</i> , 2015, 241, 130-137.	0.4	54
20	CRP and Adiponectin and Its Oligomers in the Metabolic Syndrome. <i>American Journal of Clinical Pathology</i> , 2008, 129, 815-822.	0.4	51
21	Increased Adipose Tissue Insulin Resistance in Metabolic Syndrome: Relationship to Circulating Adipokines. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 503-507.	0.5	45
22	Comparison of Cardiac Troponin I and Lactate Dehydrogenase Isoenzymes for the Late Diagnosis of Myocardial Injury. <i>American Journal of Clinical Pathology</i> , 1996, 106, 705-708.	0.4	44
23	Role of C-reactive protein in the assessment of cardiovascular risk. <i>American Journal of Cardiology</i> , 2003, 91, 200-202.	0.7	43
24	Management of Hypertriglyceridemia in the Diabetic Patient. <i>Current Diabetes Reports</i> , 2010, 10, 316-320.	1.7	41
25	Amino acid levels in nascent metabolic syndrome: A contributor to the pro-inflammatory burden. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 465-469.	1.2	38
26	Increased mast cell abundance in adipose tissue of metabolic syndrome: relevance to the proinflammatory state and increased adipose tissue fibrosis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E504-E509.	1.8	36
27	Endotoxemia of Metabolic Syndrome: A Pivotal Mediator of Meta-Inflammation. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 454-456.	0.5	34
28	Exploratory lipidomics in patients with nascent Metabolic Syndrome. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 791-794.	1.2	33
29	Clinical Utility of Lactate Dehydrogenase. <i>American Journal of Clinical Pathology</i> , 2015, 143, 158-159.	0.4	31
30	Increased eosinophils in adipose tissue of metabolic syndrome. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 535-538.	1.2	31
31	Subcutaneous adipose tissue biology in metabolic syndrome. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2018, 33, .	0.3	29
32	Antioxidants and vitamins to reduce cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2000, 2, 342-351.	2.0	27
33	Hyperglycemia Induces Toll-Like Receptor Activity Through Increased Oxidative Stress. <i>Metabolic Syndrome and Related Disorders</i> , 2016, 14, 239-241.	0.5	26
34	Increased Neutrophil Count in Nascent Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 128-131.	0.5	25
35	Exploratory metabolomics of nascent metabolic syndrome. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 212-216.	1.2	20
36	The platelet to high density lipoprotein \hat{c} holesterol ratio is a valid biomarker of nascent metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3403.	1.7	20

#	ARTICLE	IF	CITATIONS
37	Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. <i>Clinical Biochemistry</i> , 2016, 49, 1202-1204.	0.8	19
38	Cadmium and atherosclerosis: Heavy metal or singing the blues?. <i>Atherosclerosis</i> , 2016, 249, 230-232.	0.4	19
39	Fetuin-A is also an adipokine. <i>Lipids in Health and Disease</i> , 2019, 18, 73.	1.2	18
40	Detection by Immunofixation of M Proteins in Hypogammaglobulinemic Patients With Normal Serum Protein Electrophoresis Results. <i>American Journal of Clinical Pathology</i> , 2007, 127, 746-751.	0.4	16
41	Pseudoinulinoma in a White Man With Autoimmune Hypoglycemia Due to Anti-Insulin Antibodies. <i>American Journal of Clinical Pathology</i> , 2014, 142, 689-693.	0.4	16
42	Increased inflammasome activity in subcutaneous adipose tissue of patients with metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3383.	1.7	16
43	The relationship between tyramine levels and inflammation in metabolic syndrome. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2019, 40, .	0.3	14
44	Neutrophil and monocyte ratios to high-density lipoprotein-cholesterol and adiponectin as biomarkers of nascent metabolic syndrome. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	14
45	Dysregulation of monocyte biology in metabolic syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 213-221.	1.2	12
46	Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 23-28.	1.2	11
47	The role of the high-mobility group box1 protein in Toll like receptor pathway in diabetic vascular disease. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1186-1191.	1.2	11
48	Selective increase in monocyte p38 mitogen-activated protein kinase activity in metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 93-96.	0.9	11
49	Targeting inflammation to reduce ASCVD in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 1-3.	1.2	11
50	DPP-4 inhibitors and atherosclerosis: The promise. <i>Atherosclerosis</i> , 2013, 227, 224-225.	0.4	10
51	Increased fibrosis and angiogenesis in subcutaneous gluteal adipose tissue in nascent metabolic syndrome. <i>Diabetes and Metabolism</i> , 2017, 43, 364-367.	1.4	10
52	Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2018, 35, .	0.3	10
53	Chemerin Ratios to HDL-cholesterol and Adiponectin as Biomarkers of Metabolic Syndrome. <i>Endocrine Research</i> , 2020, 45, 241-245.	0.6	10
54	Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 550-553.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Diagnosis of Familial Hypercholesterolemia: Table 1. American Journal of Clinical Pathology, 2016, 145, 437-439.	0.4	8
56	Both the platelet count and the platelet: lymphocyte ratio are not increased in nascent metabolic syndrome. Platelets, 2019, 30, 1057-1058.	1.1	7
57	The neutrophil count is superior to the neutrophil/lymphocyte ratio as a biomarker of inflammation in nascent metabolic syndrome. Annals of Clinical Biochemistry, 2019, 56, 715-716.	0.8	7
58	A comparison of the ratios of C-reactive protein and triglycerides to high-density lipoprotein-cholesterol as biomarkers of metabolic syndrome in African Americans and non-Hispanic Whites. Journal of Diabetes and Its Complications, 2022, 36, 108231.	1.2	7
59	The Ratios of Triglycerides and C-reactive protein to High density-lipoprotein -cholesterol as valid biochemical markers of the Nascent Metabolic Syndrome. Endocrine Research, 2021, 46, 196-202.	0.6	6
60	Hypoglycemia and the predisposition to cardiovascular disease: Is the pro-inflammatory-pro-coagulant diathesis a plausible explanation?. Atherosclerosis, 2016, 251, 504-506.	0.4	5
61	Modern Management of Familial Hypercholesterolemia. Metabolic Syndrome and Related Disorders, 2016, 14, 463-467.	0.5	5
62	Plasma fetuin-A does not correlate with monocyte TLR4 in humans. Diabetologia, 2016, 59, 222-223.	2.9	5
63	Monocyte cell adhesion molecule receptors in nascent metabolic syndrome. Clinical Biochemistry, 2016, 49, 505-507.	0.8	5
64	Inflammation and atherosclerosis: fulfilling Koch's postulates. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 5-6.	1.0	5
65	Antisense to protein kinase C-alpha and p47phox attenuates the pro-inflammatory effects of human C-reactive protein in macrophages of biobreeding diabetic rats. Diabetes and Vascular Disease Research, 2012, 9, 315-319.	0.9	4
66	What Is the Role of the Clinical Laboratory in the New ACC/AHA Guidelines for the Treatment of Blood Cholesterol in Adults?. American Journal of Clinical Pathology, 2014, 141, 772-773.	0.4	4
67	The evolving role of toll-like receptors in diabetic vascular complications. Journal of Diabetes and Its Complications, 2015, 29, 617-620.	1.2	4
68	Endosomal Toll-Like Receptor Status in Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2015, 13, 477-480.	0.5	4
69	Factors that promote macrophage homing to adipose tissue in metabolic syndrome. Journal of Diabetes and Its Complications, 2016, 30, 1434-1436.	1.2	4
70	Preliminary Report of Inflammatory Markers, Oxidative Stress, and Insulin Resistance in Adolescents of Different Ethnicities. Metabolic Syndrome and Related Disorders, 2016, 14, 182-186.	0.5	4
71	Quantification of daratumumab in the serum protein electrophoresis. Clinical Chemistry and Laboratory Medicine, 2017, 55, e27-e28.	1.4	4
72	AHA/ACC/Multisociety Cholesterol Guidelines: highlights. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471988157.	1.0	4

#	ARTICLE	IF	CITATIONS
73	Management of diabetic dyslipidemia: Navigating the new American and European Guidelines. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 877-879.	1.8	4
74	Metabolites that activate the inflammasome in nascent metabolic syndrome. Journal of Diabetes and Its Complications, 2021, 35, 107836.	1.2	4
75	Opinion paper: Is the Friedewald equation obsolete?. Clinica Chimica Acta, 2021, 514, 122-124.	0.5	4
76	Chemerin levels in metabolic syndrome: a promising biomarker. Archives of Physiology and Biochemistry, 2023, 129, 1009-1011.	1.0	4
77	PCSK9 Inhibitors: The Next Frontier in Low-Density Lipoprotein Lowering. Metabolic Syndrome and Related Disorders, 2015, 13, 99-101.	0.5	3
78	Nutrition therapy for diabetes: Implications for decreasing cardiovascular complications. Journal of Diabetes and Its Complications, 2017, 31, 1477-1480.	1.2	3
79	Potential implications of redefining the hypertriglyceridemia of metabolic syndrome. Hormone Molecular Biology and Clinical Investigation, 2019, 40, .	0.3	3
80	Decreased homoserine levels in metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 555-559.	1.8	3
81	Effect of Aloe vera Supplements in Patients with Preâ€Diabetes. FASEB Journal, 2009, 23, 900.7.	0.2	3
82	The Paradox of Increased Trimethylamine-N-Oxide Levels Following Bariatric Surgery. Metabolic Syndrome and Related Disorders, 2016, 14, 195-196.	0.5	2
83	Excessive hypercortisolemia due to ectopic Cushingâ€™s syndrome requiring extending the reportable range for plasma cortisol for management. Clinical Chemistry and Laboratory Medicine, 2017, 56, e7-e9.	1.4	2
84	Optimum lipid testing for diabetic patients to enhance clinical care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 461-464.	1.8	2
85	Epigenetic regulation of high glucoseâ€induced proinflammatory cytokine production in monocytes by curcumin. FASEB Journal, 2010, 24, 1030.9.	0.2	2
86	Severe Hyperglycemia Down Regulates Tollâ€Like Receptors on Neutrophils: Implications for Propensity to Infections in Diabetics. FASEB Journal, 2013, 27, 648.11.	0.2	2
87	No Benefit of Saxagliptin on Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Potential Explanations. Metabolic Syndrome and Related Disorders, 2014, 12, 157-158.	0.5	1
88	Therapeutic Monoclonal Antibodies and the Value of the Free Light Chain Assay in Myeloma. American Journal of Clinical Pathology, 2018, 150, 468-469.	0.4	1
89	Oral Pharmacotherapy as Alternative Treatment for Type 2 Diabetes Mellitus in a 61 Year Old Ethnic Filipino Man with Insulin Allergies. Laboratory Medicine, 2019, 50, 93-95.	0.8	1
90	Validation of Fibroblast Growth Factor 23 Assays. journal of applied laboratory medicine, The, 2020, 5, 819-821.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Update on Lipids and Lipoproteins. JAMA - Journal of the American Medical Association, 2021, 325, 400.	3.8	1
92	A Patient with Genetic Bisalbuminemia. American Journal of the Medical Sciences, 2021, 362, e53-e54.	0.4	1
93	Letter to the Editor from Jialal and Sood: "New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation Using Specific Cortisol Assays" Journal of the Endocrine Society, 2021, 5, bvab112.	0.1	1
94	Leukocytes, platelets and cardiovascular diseases. Atherosclerosis, 2021, 329, 50-51.	0.4	1
95	An African American Male Patient with Rare Type B Insulin Resistance Syndrome. Laboratory Medicine, 2021, , .	0.8	1
96	OUP accepted manuscript. Laboratory Medicine, 2022, , .	0.8	1
97	Differential effects of oral vs. transdermal estrogen replacement therapy on serum amyloid a in postmenopausal women. American Journal of Hypertension, 2004, 17, S245.	1.0	0
98	Ezetimibe "Statin Combination to Reduce Cardiovascular Events: The Evidence Base. Metabolic Syndrome and Related Disorders, 2015, 13, 327-328.	0.5	0
99	Cellular Signaling in Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2015, 13, 371-372.	0.5	0
100	The skinny on metabolic syndrome in adolescents. Translational Pediatrics, 2016, 5, 97-99.	0.5	0
101	Folate Insufficiency Due to Celiac Disease in a 49-Year-Old Woman of Southeast Asian-Indian Ethnicity: Table 1.. Laboratory Medicine, 2016, 47, 259-262.	0.8	0
102	Interpretation of protein electrophoresis. Annals of Clinical Biochemistry, 2017, 54, 622-622.	0.8	0
103	Normal uric acid levels in nascent metabolic syndrome patients residing in northern California. Journal of Diabetes and Its Complications, 2017, 31, 1639-1640.	1.2	0
104	Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?. Therapeutic Advances in Cardiovascular Disease, 2021, 15, 175394472110427.	1.0	0
105	Dose "response study of purified lycopene on biomarkers of oxidative stress. FASEB Journal, 2006, 20, A549.	0.2	0
106	Effect of High Dose Alpha Tocopherol Therapy on Carotid Atherosclerosis, Biomarkers of Oxidative Stress and Inflammation in Patients with Coronary Artery Disease. FASEB Journal, 2006, 20, A132.	0.2	0
107	In vivo Evidence of C "Reactive Protein" Mediated Metalloproteinase "9 Induction from Rat Macrophages: Molecular Insights. FASEB Journal, 2008, 22, 903.4.	0.2	0
108	Simvastatin (40mg/day) Reduced the Activity of Circulating Plasminogen Activator Inhibitor 1 in Volunteers with Metabolic Syndrome. FASEB Journal, 2008, 22, 1123.21.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Pioglitazone treatment inhibits Tollâ€like receptor expression in vitro and in vivo. FASEB Journal, 2009, 23, 45.6.	0.2	0
110	CRP Impairs Endothelial Glycocalyx: Role in Promoting Endothelial Dysfunction. FASEB Journal, 2009, 23, 357.5.	0.2	0
111	Effects of epigallocatechin gallate on regulatory T cell number and function in obese versus lean volunteers. FASEB Journal, 2010, 24, 541.11.	0.2	0
112	Low vitamin D levels in North American Adults with metabolic syndrome. FASEB Journal, 2011, 25, 223.2.	0.2	0
113	Increased Monocyte Tollâ€like receptor Activity In Patients With Metabolic Syndrome. FASEB Journal, 2012, 26, 125.2.	0.2	0
114	A Novel small molecule Inhibitor to Câ€Reactive Protein attenuates CRP's Proâ€Inflammatory Effects Inâ€Vivo. FASEB Journal, 2013, 27, 379.12.	0.2	0
115	Biogenic Amines and Inflammatory Status in Nascent Metabolic Syndrome. FASEB Journal, 2018, 32, 817.10.	0.2	0
116	Defining the Cytokine Storm Syndrome of COVID-19: Role of the Clinical Laboratory. Annals of Clinical and Laboratory Science, 2020, 50, 703-705.	0.2	0
117	Letter to the Editor From Jialal: â€œHigher Incidence of Metabolic Syndrome in Black Women With Polycystic Ovary Syndrome: A Longitudinal Studyâ€ Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	0
118	Reporting Apparent Biclonal Immunoglobulin-A Monoclonal Proteins with Identical Light Chains. Annals of Clinical and Laboratory Science, 2020, 50, 541-544.	0.2	0
119	Comparison of the triglyceride-waist circumference and the C-reactive protein-waist circumference indices in nascent metabolic syndrome. International Journal of Physiology, Pathophysiology and Pharmacology, 2021, 13, 126-131.	0.8	0